Caricamento...
Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer
KRAS mutations are associated with tumor resistance to EGFR TKIs (erlotinib, gefitinib) and to monoclonal antibody against EGFR (cetuximab). Targeted treatment of mutated RAS patients is still considered as a challenge. Inhibitors of c-Met (onartuzumab or tiwantinib) and MEK (selumetinib—a dual inhi...
Salvato in:
| Pubblicato in: | Clin Exp Med |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer International Publishing
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4844634/ https://ncbi.nlm.nih.gov/pubmed/25902737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10238-015-0349-2 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|